MAOA Gene polymorphisms and response to mirtazapine in major depression

Human Psychopharmacology

Volumn 24, Issue 4, 2009, Pages 293-300

  Tzeng, Dong Sheng ^a,b   Chien, Chia Chang ^a   Lung, For Wey ^a,b,c   Yang, Chun Yuh ^b  

^a KAOHSIUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL DEFENSE UNIVERSITY   (Taiwan)

Author keywords

Apolipoprotein E; Hamilton's depression rating scale; Major depression; MAOA gene polymorphism; Mirtazapine

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; APOLIPOPROTEIN E; GENOMIC DNA; MIRTAZAPINE; AMINE OXIDASE (FLAVIN CONTAINING); DNA; DRUG DERIVATIVE; MIANSERIN; MONOAMINE OXIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DNA DETERMINATION; DNA EXTRACTION; DRUG RESPONSE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; REMISSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCORING SYSTEM; TAIWAN; VARIABLE NUMBER OF TANDEM REPEAT; VENOUS BLOOD; GENETICS; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 68049137696     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1024     Document Type: Article

References (42)

1. Anderson IM. 2000. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58(1): 19-36.
2. Bagby RM, Ryder AG, Schuller DR, Marshall MB. 2004. The Hamilton depression rating scale: has the gold standard become a lead weight? Am J Psychiat 161: 2163-2177.
3. Baldessarini RJ. 1989. Current status of antidepressants: clinical pharmacology and therapy. J Clin Psychiat 50: 117-126.
4. Behnke K, Sogaard J, Martin S, et al. 2003. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharmacol 23: 358-364.
5. Benkert O, Szegedi A, Kohnen R. 2000. Mirtazapine compared with paroxetine in major depression. J Clin Psychiat 61: 656-663.
6. Bruijn JA, Moleman P, Mulder PG, Van den Broek WW. 1999. Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry 32: 87-92.
7. Chen ZY, Hotamisligil GS, Huang JK, et al. 1991. Structure of the human gene for monoamine oxidase type A. Nucleic Acids Res 19(16): 4537-4541.
8. Claghorm JL, Lasem MD. 1995. A double-blind, placebo-controlled study of Org 3770 in depressed outpatients. J Affect Disorders 34: 165-171.
9. Cole MG, Bellavence F. 1997. Depression in elderly medical inpatients: a meta-analysis of outcomes. CMAJ 157(8): 1055-1060.
10. Cole MG, Bellavance F, Mansour A. 1999. Prognosis of depression in elderly community and primary care populations: a systematic review and meta-analysis. Am J Psychiat 156: 1182-1189.
11. Cummings JL. 1993. The neuroanatomy of depression. J Clin Psychiat 54: 14-20.
12. Delgado PL, Kahn RS. 2002. Sequential catecholamine and serotonin depletion in mirtazapine-treated depressed patients. Int J Neuropsychopharmacol 5(1): 63-66.
13. Delgado PL, Miller HL, Salomon RM, et al. 1993. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychol Bull 29: 389-396.
14. Frisch A, Postilnick D, Rockah R, et al. 1999. Association of unipolar major depressive disorder with genes of the serotonergic and dopaminergic pathways. Mol Psychiatr 4(4): 389-392.
15. Gutierrez B, Arias B, Gasto C, et al. 2004. Association analysis between a functional polymorphism in the momoamine oxidase A gene promoter and severe mood disorders. Psychiat Genet 14(4): 203-208.
16. Haapasalo-Pesu KM, Vuola T, Lahelma L, Marttunen M. 2004. Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study. J Child Adol Psychop 14: 175-184.
17. Hixon J, Vernier DT. 1990. Restriction iso-typing of human ApoE by gene amplification and cleavage with HhaI. J Lipid Res 31: 545-548.
18. Hong CJ, Hu WH, Chen CC, Hsiao CC, Tsai SJ, Ruwe FJ. 2003. A double-blind, treatment with mirtazapine or fluoxetine in depressed Chinese patients. J Clin Psychiat 64: 921-926.
19. Hooijer C, Zitman FG, Griez E, van Tilburg W, Willemse A, Dinkgreve MA. 1991. The Hamilton depression rating scale (HDRS); changes in scores as a function of training and version used. J Affect Disord 22: 21-29.
20. Hoyberg OJ, Maragakis B, Mullin J, et al. 1996. A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr Scand 93: 184-190.
21. Hwang JP, Yang CH, Hong CJ, Lirng JF, Yang YM, Tsai SJ. 2006. Association of APOE genetic polymorphism with cognitive function and suicide history in geriatric depression. Dement Geriatr Cogn Disord 22(4): 334-338.
22. Kahn MC. 1995. A randomized, double-blind, placebo-controlled, 5 week study of Org 3770 in major depression. Hum Psychopharmacol 10: 119-124.
23. Leinonen E, Skarstein J, Behnke K, Agren H, Helsdingen JT. 1999. Efficacy and tolerability of mirtazapine vs. citalopram: a double-blind, randomized study in patients with major depressive disorder. Int Clin Psychopharm 14: 329-337.
24. Leucht S, Davis JM, Engel RR, Kane JM, Wagenpfeil S. 2007. Defining "response" in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacol 32(9): 1903-1910.
25. Mahley RW. 1988. Apolipoprotein E: cholesterol transport protein with an expanding role in cell biology. Science 240: 622-630.
26. Meyer-Lindenberg A, Buckholtz JW, Kolachana B, et al. 2006. Neural mechanisms of genetic risk for impulsivity and violence in humans. Proc Natl Acad Sci USA 103(16): 6269-6274.
27. Murphy GM, Kremer C, Rodrigues H, Schatzberg AF. 2003. The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively intact elderly depressed patients. Biol Psychiatry 54(7): 665-673.
28. Murphy GM, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. 2004. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiat 61: 1163-1169.
29. Richelson E. 1991. Biological basis of depression and therapeutic relevance. J Clin Psychiat 52(8): 353.
30. Richelson E, Nelson A. 1984. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 230: 94-102.
31. Rigaud AS, Traykov L, Caputo L, et al. 2001. Association of the apolipoprotein E epsilon4 allele with late-onset depression. Neuroepidemiology 20: 268-272.
32. Roose SP, Miyazaki M, Devanand D, et al. 2004. An open trial of venlafaxine for the treatment of late-life atypical depression. Int J Geriatr Psychiatry 19(10): 989-994.
33. Sabol SZ, Hu S, Hamer D. 1998. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 103: 273-279.
34. Schwab JJ, Bialow MR, Clemmons RS, Holzer CE. 1967. Hamilton rating scale for depression with medical in-patients. Brit J Psychiat 113: 83-88.
35. Small GW, Hamilton SH, Bystritsky A, Meyers BS, Nemeroff CB. 1995. Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression, fluoxetine collaborative study group. Int Psychogeriatr 7: 41-53.
36. Smith WT, Glaudin V, Panagides J, Gilvary E. 1990. Mirtazapine vs. amitryptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacol Bull 26: 191-196.
37. Tadic A, Müller MJ, Rujescu D, et al. 2007. The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am J Med Genet B 144(3): 325-331.
38. Tzeng DS, Lian LC, Chang CU, et al. 2007. Healthcare in schizophrenia: effectiveness and progress of a redesigned care network. BMC Health Services Research 7 129.
39. Vanyukov MM, Moss HB, Yu LM, Tarter RE, Deka R. 1995. Preliminary evidence for an association of a dinucleotide repeat polymorphism at the MAOA gene with early onset alcoholism/substance abuse. Am J Med Genet A 60(2): 122-126.
40. Weissman MM, Merikangas KR, Wickramaratne P, et al. 1986. Understanding the clinical heterogeneity of major depression using family data. Arch Gen Psychiat 43(5): 430-434.
41. Wenham PR, Price WH, Blundell G. 1991. Apoliprotein E genotyping by one gate PCR. Lancet 337: 1158-1159.
42. Zeger SL, Liang KY. 1986. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42: 121-130.